Celltrion Healthcare's Remsima (infliximab biosimilar)

Remsima, developed by Celltrion Healthcare, is a biosimilar medication to infliximab, used to treat autoimmune conditions like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. As a biosimilar, it is a highly similar version of the original biologic drug but typically offered at a lower cost. Remsima works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha), which causes inflammation and tissue damage in these conditions. It is administered via infusion and helps reduce symptoms, improve quality of life, and prevent disease progression, providing an effective and more accessible treatment option for patients.